RxDoctor Payments Data

Gary Feldman

Sleep Medicine · Irvine, CANPI 1891715009

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Shionogi Inc at 30.3% of the total. 2025 is the largest year on record at $1,893, 9.6 times the $198 reported in 2019.

$4,200in general payments, 2019–2025

Across 96 payments — averaging $43.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$1K
  • Janssen Scientific Affairs, LLC$1K
  • Jazz Pharmaceuticals Inc.$626
  • Inspire Medical Systems, Inc.$209
  • Harmony Biosciences LLC$206
  • Supernus Pharmaceuticals, Inc.$198
  • plus $689 from 10 others
$45,103in research payments, 2019–2025

Across 33 payments — averaging $1366.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Jazz Pharmaceuticals Inc.$45K

What the payments were for

  • Speaking & faculty fees$1,00024%
  • Travel & lodging$99324%
  • Food & beverage$1,99548%
  • Education$2125%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,200 in reported general payments places this provider in the 70th percentile of 200 sleep medicine providers in California.

See all sleep medicine providers in California

Medicare billing

Part B allowed, 2024
$32,209
Medicare patients
49
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$957
Minocycline Hcl16$356
Fluoxetine Hcl11$111
Clonazepam11$64
Sertraline Hcl15$64
Citalopram HbrCitalopram Hydrobromide25$21

Paid to pharmacies, not to this prescriber.

Other sleep medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →